Form 4: Daveen Chopra Disposes of 2,500 EW Shares, Ownership Now 30,996

Rhea-AI Filing Summary

Edwards Lifesciences (EW) insider sale disclosed on Form 4. Reporting person Daveen Chopra, listed as an officer (CVP, TMTT), sold 2,500 shares of Edwards Lifesciences common stock on 08/25/2025 at a weighted average price of $81.946 per share. After the sale the filing reports 30,996 shares beneficially owned by the reporting person, held directly. The filing states the reported sale was executed in multiple trades at prices ranging from $81.9401 to $81.9500 and that the weighted average price is provided; the filer offers to supply detailed trade-by-trade information upon request. The form notes it reflects changes in beneficial ownership only and does not list other securities the reporting person may own.

Positive

• Complete disclosure of sale quantity, weighted-average price, and post-transaction ownership
• Execution range disclosed (prices from $81.9401 to $81.9500) with offer to provide trade-level details upon request

Negative

• None.

Insights

Securities Analyst

TL;DR: Officer sale of 2,500 EW shares reduces direct holdings to 30,996; transaction appears routine and not materially large.

The sale on 08/25/2025 of 2,500 shares at a weighted average of $81.946 is a clear, single-day reduction of direct holdings by the reporting officer. The filing discloses execution in multiple trades within a narrow price band, and the filer commits to provide transaction details if requested. There is no indication in this Form 4 of derivative transactions, changes to compensation arrangements, or other concurrent disclosures that would suggest a material corporate event. Given the absolute size disclosed and absence of additional context, this appears to be a routine insider sale rather than a company-specific signal.

Corporate Governance Expert

TL;DR: The disclosure meets Section 16 requirements and provides the required weighted-average price note; no governance red flags visible.

The Form 4 identifies the reporting person as an officer (CVP, TMTT) and correctly reports the sale quantity, post-transaction direct ownership, and price disclosure including the range of trade prices. The remarks explicitly state the form covers only beneficial ownership changes and not other holdings. From a governance perspective, the filing is complete for the transaction reported and includes an agent signature. The form does not show any suspicious timing or related-party transactions within this document.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chopra Daveen

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CA 92614

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, TMTT

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/25/2025		S		2,500	D	$81.946(1)	30,996	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $81.9401 to $81.9500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	08/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Daveen Chopra sell in the Edwards Lifesciences (EW) Form 4?

The filer sold 2,500 shares of Edwards Lifesciences common stock on 08/25/2025.

At what price were the EW shares sold according to the Form 4?

The weighted-average sale price reported is $81.946 per share, with trades ranging from $81.9401 to $81.9500.

How many EW shares does the reporting person own after the transaction?

The Form 4 reports 30,996 shares beneficially owned following the reported sale.

What is the reporting person’s role at Edwards Lifesciences per the filing?

The filing identifies the reporting person, Daveen Chopra, as an officer with title listed as CVP, TMTT.

Does the Form 4 disclose any derivative transactions or other securities?

No. Table II for derivative securities shows no entries and the form states it only reflects changes in beneficial ownership of common stock.